Khona Scientific will apply biomanufacturing technology to create bioidentical steroid hormones that align with EVEXIAS’ leading hormone therapy approaches.
BOULDER, CO, UNITED STATES, July 30, 2026 /EINPresswire.com/ — Khona Scientific, a frontrunner in biomanufacturing for intricate natural product compounds, is thrilled to reveal the signing of a Letter of Intent (LOI) with EVEXIAS, a top provider of hormone replacement and optimization therapies. Via deliberate planning and meticulous verification, the two entities aim to construct the steroid hormone supply chain of the future, right now.
Steroid hormones rank among the body’s most potent chemical messengers. These substances affect the operation of virtually every organ system and biological process, playing vital roles in metabolism, aging, immunity, reproductive health, bone integrity, cardiovascular function, and cognition. Therefore, shortages in steroid hormone levels produce extensive health consequences that can be addressed through customized hormone treatments, such as those supplied by EVEXIAS.
Just as deficits in steroid hormone levels can cause harmful effects in patients, weaknesses in the supply chains for these hormones can similarly generate adverse outcomes for treatment providers like EVEXIAS. These supply challenges can be overcome through breakthroughs in steroid hormone manufacturing. At present, these compounds are sourced nearly entirely from India and China. Khona Scientific’s move into steroid hormones is driven by a goal to offer partners such as EVEXIAS additional options for sourcing APIs to satisfy rising demand from patients and physicians. Building resilience through multiple supply channels is the core aim of the partnership between Khona Scientific and EVEXIAS.
The initiative revolves around leveraging Khona Scientific’s BiDS™ platform to generate bioidentical steroid hormones for incorporation into EVEXIAS’ hormone therapy products following strict validation. BiDS™ is a flexible, modular system for creating complex active pharmaceutical ingredients (APIs) using plentiful, low-cost, renewable sugars as raw materials. The technology functions like a ‘molecular assembly line’ – it boosts yield, quality, throughput, and efficiency by arranging enzymes from multiple pathways in the ideal sequence inside a host cell to generate the target compound. This structure maximizes output and resolves the bottlenecks inherent in older methods. Consequently, this allows scalable, affordable, on-demand API production that does not rely on specialized inputs. By separating steroid hormone API manufacturing from agricultural supply chains, Khona Scientific’s BiDS™ technology can assist EVEXIAS in maintaining the continuity and uniformity of care for patients receiving its personalized hormone therapy protocols.
“Our mission has always been to provide patients and physicians with safe, effective, and dependable treatment options” said Dan DeNeui, CEO of EVEXIAS. “We look forward to exploring how Khona Scientific can contribute to this mission by facilitating supply chain diversification for our hormone therapy offerings.”
Paul Orlady, CEO of Khona Scientific, says, “We are eager to showcase the capabilities of Khona Scientific’s technology by delivering a purpose-built production pipeline that will enhance the supply chain for EVEXIAS’ industry-leading hormone therapy segment. This constitutes an important first step for the Companies’ mutual objective of ensuring better health outcomes for patients seeking relief from a number of conditions.”
Several steroid hormones are covered under the LOI, such as progesterone, estradiol, estrone, and estriol. Estradiol is a primary treatment for menopause symptoms like hot flashes and night sweats, as well as for preventing bone loss (osteoporosis). Progesterone is often paired with estradiol in hormone therapy regimens to address menopausal symptoms and to ensure endometrial protection during treatment. Estradiol and progesterone are also used in non-menopausal contexts, including infertility treatment, managing polycystic ovarian syndrome (PCOS), and in assisted reproductive technologies.
About EVEXIAS
EVEXIAS is a frontrunner in hormone optimization, functional medicine, and proactive longevity care, assisting practitioners in moving beyond symptom management toward precise, root-cause treatment. Through the proprietary EvexiPEL® Method, advanced diagnostics, and thorough clinical education, EVEXIAS provides a nationwide network of providers with the tools, training, and ongoing strategic support to deliver personalized, data-driven care with confidence and consistency. By merging clinical innovation, practice growth strategies, and an education-first approach, EVEXIAS helps enhance patient outcomes, strengthen practice performance, and advance the future of integrative medicine. Find out more at http://www.evexias.com/.
About Khona Scientific
Khona Scientific is a synthetic biology pioneer deploying modular biomanufacturing solutions for creating complex natural product compounds from renewable, basic feedstocks. The Company’s BiDS™ platform unlocks the full potential of Key Starting Material (KSM) and Active Pharmaceutical Ingredient (API) biomanufacturing by redesigning complex biosynthetic pathways to operate as high-throughput molecular assembly lines. Khona Scientific is currently applying its technology for producing KSMs and generic APIs where quality, reliability, and adaptability are critical. Learn more at http://www.khonascientific.com/.
Paul Orlady
Khona Scientific Inc.
Paul@khonascientific.com
